SMN1 Gene Sequencing (Spinal Muscular Atrophy Type 4) Genetic Test

Executive Summary & Core Metrics

This advanced genetic test utilizes Next Generation Sequencing (NGS) to analyze the SMN1 gene for the diagnosis of adult-onset Spinal Muscular Atrophy Type 4 (SMA Type 4), offering a diagnostic sensitivity of 99.9%. Fully accredited and compliant with DHA regulatory standards, the test is supported by VIP mobile phlebotomy and temperature-controlled cold-chain home collection services available daily from 8 AM to 11 PM.

99.9% Diagnostic Sensitivity – ISO/IEC 15189 accredited processing, validated by DHA standards.
Hospital-Grade Home Collection – ISO-certified cold-chain logistics & VIP mobile phlebotomy (8 AM – 11 PM daily).
Post-Test Clinical Guidance – Telephonic result interpretation by specialist advisors.
Direct Insurance Billing Verification – WhatsApp at +971 54 548 8731.

Test Overview & Methodology

Spinal Muscular Atrophy Type 4 (SMA Type 4) is a rare, adult-onset neuromuscular disorder characterized by proximal muscle weakness. The SMN1 gene NGS test provides a comprehensive analysis of the entire gene, identifying point mutations, copy number variations (CNVs), and deep intronic variants that standard MLPA assays may miss.

Feature	Our Test (SMN1 NGS)	Closest Alternative (MLPA‑only)
Methodology	Next Generation Sequencing (full gene)	Multiplex Ligation‑dependent Probe Amplification
Detection Spectrum	Point mutations, CNVs, deep intronic variants	Only large deletions/duplications (exon 7/8)
Turnaround Time	3–4 weeks	2–3 weeks
Diagnostic Sensitivity	~99.9%	95–98% for common deletions

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics specialist, I emphasize that the SMN1 NGS test offers the highest sensitivity for detecting pathogenic variants causing SMA Type 4. However, molecular findings must be meticulously correlated with the patient's clinical phenotype and family pedigree. Patients should never independently alter their therapeutic regimen based on genetic results alone.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Clinical Advisory & Medication Warning

IMPORTANT: Genetic test results are powerful diagnostic tools, but they do not replace clinical judgment. Do not discontinue, adjust, or initiate any prescribed medication or therapy without direct consultation with your treating neurologist or genetic specialist.

Test Exclusion Criteria & ER Red Flags

Exclusion: Recent blood transfusion (within 2 weeks), active systemic infection, inability to provide informed consent.
Exclusion: Minors without parental/guardian consent as per Federal Law No. 2 of 2019.
Exclusion: Individuals who have undergone whole‑blood replacement therapy within the last 7 days.
ER Red Flag: Sudden worsening of muscle weakness, difficulty swallowing or breathing, severe choking episodes, or loss of ambulation – seek emergency care immediately.

Patient FAQ & Clinical Guidance

1. What is the SMN1 gene spinal muscular atrophy type 4 NGS test and who should take it?

This advanced genetic test analyzes the entire SMN1 gene using Next Generation Sequencing to diagnose adult‑onset spinal muscular atrophy type 4. It is recommended for individuals with progressive muscle weakness, a family history of SMA, or those identified as carriers. The test can confirm a suspected clinical diagnosis, differentiate SMA Type 4 from other motor neuron diseases, and inform reproductive planning.

2. How do I prepare for the test and is home collection available?

A pre‑genetic counselling session is required to review your clinical history and construct a family pedigree. A hospital‑grade home blood collection service is available daily from 8 AM to 11 PM using temperature‑controlled cold‑chain transport. The acceptable sample types include peripheral whole blood, extracted DNA, or a dried blood spot on an FTA card. Please inform our team of any anticoagulant or immunosuppressant medications prior to collection.

3. How long does it take to receive results and what do they mean?

Results are delivered within 3 to 4 weeks in a secure digital report. A positive result indicates the presence of a pathogenic SMN1 mutation, which must be correlated with your clinical picture by a specialist. A negative result significantly reduces the likelihood of SMA Type 4, although other genetic or acquired causes may still be considered. A genetic counsellor will explain the implications and recommend any necessary family cascade testing.

UAE Regulatory & Data Privacy Adherence

All genetic testing procedures at DNA Labs UAE strictly adhere to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). Genetic data is handled with encrypted, DHA-compliant security measures.

Clinical & Logistical Metadata

Test Name	SMN1 Gene Sequencing (Spinal Muscular Atrophy Type 4)
Price (AED)	2,800
Turnaround Time	3–4 weeks
Sample Type / Matrix	Peripheral Whole Blood, Extracted DNA, or Dried Blood Spot
Methodology Used	Next Generation Sequencing (NGS) with Bioinformatic Analysis
ICD-10-CM Code	G12.1, Z14.8, Z13.79
LOINC Code	78296-5
DHA Facility License & Laboratory Address	1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE